FDA Halts Clinical Test of Zafgen Diabetes Drug, Stock Price Tumbles | Enterpreneurship

0
Want create site? Find Free WordPress Themes and plugins.

Want create site? Find Free WordPress Themes and plugins.

The has ordered to suspend a mid-stage study testing its experimental , an apparent precautionary move.

A hold patient enrollment and also stops already enrolled patients from receiving the study drug due to a potential safety risk. No safety problems have been reported for the drug, ZGN-1061, so far. But Zafgen (NASDAQ: ZFGN) said Monday that the FDA’s letter cited the “possibility of cardiovascular safety risk” based on the company’s earlier obesity drug, which acts in a similar way as ZGN-1061. Two years ago, the deaths of two patients in a late-stage study of the… Read more »

UNDERWRITERS AND PARTNERS



Did you find apk for android? You can find new Free Android Games and apps.
Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.